Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan

研究成果: Article同行評審

摘要

From January 2019 to May 2021, 11 children underwent allogeneic stem cell transplantation at our institute. Four of them received letermovir for cytomegalovirus prophylaxis. Three children, none of whom received prophylaxis, experienced cytomegalovirus reactivation. Letermovir is a promising medication for use in cytomegalovirus prophylaxis in children. Further studies are warranted.

原文English
頁(從 - 到)323-327
頁數5
期刊Journal of Microbiology, Immunology and Infection
55
發行號2
DOIs
出版狀態Published - 2022 4月

All Science Journal Classification (ASJC) codes

  • 免疫學和過敏
  • 免疫學與微生物學 (全部)
  • 微生物學(醫學)
  • 傳染性疾病

指紋

深入研究「Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan」主題。共同形成了獨特的指紋。

引用此